Subcutaneous absorption of biotherapeutics: knowns and unknowns.
about
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentNeonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in MiceBiodistribution and Lymphatic Tracking of the Main Neurotoxin of Micrurus fulvius Venom by Molecular Imaging.A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity.Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation.Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers.
P2860
Q28066498-DEFD46D0-5041-4F39-91E4-9F03CAA58AF8Q28082880-339BA67E-4B7D-492E-99A4-898636FD3506Q36653919-A34E7F9E-D360-4F22-A876-0E99EC324F82Q36846066-135A1E89-3C4E-46E8-8727-4B289D02AFF3Q37116075-27F9AD43-6D79-4EBB-8DF3-4347926032F2Q37337375-F0397B5A-DA32-4204-90BE-D701329875D0Q37514512-61489698-574C-4CCF-B805-99B021FBC42EQ37718004-CD65EF38-A7D4-4F04-8512-D92500EC4F2BQ38605894-9CA94F6D-320D-47B5-B66B-256813EC8A5FQ38657864-1EAE4D1A-F72D-4E0D-8467-E63BBE12685CQ38831148-7FDCB360-3443-4DED-94A0-27A4A8F0CF4EQ38842554-16BED7E9-5361-4351-9FB7-169FC52FE737Q38881426-0C8DF3A5-3F8A-40B5-81ED-9B53D19EA603Q40030334-DDD4BAA0-852D-4683-93C1-E539D17DCE48Q47231847-6B6A43FA-6F6E-44E3-A3AF-6F7DE4FB301BQ47661007-02135FA4-FA5E-45E8-8AA3-76A629C571B3Q47979735-1BBE73E1-EEE8-4246-9875-C5F930B38D75Q50034109-60C3EC30-772C-478A-8D56-119A90BF9D8CQ50140611-CB9D8E94-FA00-4DCC-B349-059833383C95Q50926502-74A9BB81-B1A7-4802-BA95-CA7F1FC961AAQ52604519-0FB0DFEC-DBF3-4D14-A7BD-BF91857560B8Q52649955-4626F9B2-AF71-49C0-987B-DD3ACCDC89DBQ55334068-8A30A57C-81BA-45E8-A396-5C3C3CC03962
P2860
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
@en
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
@nl
type
label
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
@en
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
@nl
prefLabel
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
@en
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
@nl
P356
P1476
Subcutaneous absorption of biotherapeutics: knowns and unknowns
@en
P2093
Björn Jacobsen
P304
P356
10.1124/DMD.114.059238
P577
2014-08-06T00:00:00Z